source
- Dr Cirstea on Sequencing Considerations in R/R Multiple MyelomaDiana Cirstea, MD, discusses sequencing considerations in relapsed/refractory multiple myeloma in the era of T-cell–redirecting therapies.onclive · 3mo ago↗ source
- Dr Hafron on the FDA Approval of Adjuvant Atezolizumab in MRD+ MIBCJason Hafron, MD, discusses the significance of the FDA approval of adjuvant atezolizumab for MRD+ muscle-invasive bladder cancer.onclive · 3mo ago↗ source
- Durvalumab Plus BCG Reduces High-Risk NMIBC Recurrence or Death Risk by 32% in Phase 3 POTOMAC TrialDurvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.onclive · 3mo ago↗ source